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OBJECTIVE — Individualswithtype2diabetesareathighriskforcardiovascularevents.We
evaluated the prognostic value of gated myocardial perfusion single-photon computed tomog-
raphy (SPECT) for asymptomatic diabetic patients in a Japanese population.
RESEARCH DESIGN AND METHODS — Asymptomatic patients (n  485) aged 50
years with either a maximal carotid artery intima-media thickness of 1.1 mm, or a urinary
albumin 30 mg/g creatinine or who had at least two of the following, abdominal obesity, low
HDLcholesterol,hightriglyceridelevels,andhypertension,wereenrolledat50institutions.The
patients were evaluated using gated SPECT with the stress-rest protocol and followed up for 3
years.
RESULTS — During the follow-up period, 62 (13%) events occurred, including 5 cardiac
deaths and 57 cardiovascular events. Patients with summed stress scores (SSS) of 9 had a
signiﬁcantly higher incidence (of either death or cardiovascular events) than those with SSS
scores of 9 (23 vs. 12%; P  0.009). Multivariate Cox regression analysis showed that signif-
icant variables were SSS 9, a low estimated glomerular ﬁltration rate, and being a current
smoker. Univariate Cox regression analysis showed that ticlopidine and insulin use are potent
medical modulators of cardiovascular events.
CONCLUSIONS — The incidences of cardiovascular events and death were signiﬁcantly
high in a select population of type 2 diabetic patients with SPECT abnormalities. A targeted
treatment strategy is required for asymptomatic but potentially high-risk patients with type 2
diabetes.
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C
oronary stenosis, myocardial isch-
emia,andbaselinecardiacfunctions
are important factors for the risk
stratiﬁcation of cardiac events and thus
are used to predict patient prognosis.
Among various clinical factors, diabetes
promotes atherosclerosis, resulting in a
major pathophysiological cause of cere-
bral and myocardial infarction (MI) (1).
The risk for diabetic patients without
prior MI is two- to fourfold higher than
that for nondiabetic patients, and it is
comparable with the risk for nondiabetic
patientswithpriorMI(2,3).However,be-
causeatherosclerosiscanprogressevenin
asymptomatic diabetic patients, diagnos-
ing ischemic heart diseases at an early
subclinical stage is vital (4).
The role of single-photon emission
computed tomography (SPECT) in de-
tecting myocardial ischemia and evaluat-
ing prognosis has been validated (1,5–7).
A prognostic investigation using gated
SPECT (Japanese Assessment of Cardiac
Events and Survival Study by Quantita-
tive Gated SPECT [J-ACCESS]) in a Japa-
nese population was started in 2001, and
the patients were followed up for 3 years
(3). That study revealed that diabetes is
the most important predictor of cardiac
events in the Japanese population, as has
been shown in the Finnish population
(2). Therefore, we designed the J-
ACCESS 2 prospective cohort study of
asymptomatic patients with type 2 diabe-
tes (8). The 1st year interim report clari-
ﬁed the value of gated SPECT for
individuals with type 2 diabetes (9). The
present ﬁnal report evaluates the prog-
nostic value of gated SPECT and includes
a more detailed stratiﬁcation of ischemic
cardiovasculareventsindiabeticpatients.
RESEARCH DESIGN AND
METHODS— The J-ACCESS 2 prog-
nostic registry is a prognostic cohort
study of 513 patients from 50 institutions
(8) who were registered between June
2004andSeptember2005.Certiﬁedphy-
sicians specializing in diabetes at all insti-
tutions participated in the 3-year follow-
up. The inclusion criteria included age
50 years with type 2 diabetes and either
a maximal carotid artery intima-media
thickness (max IMT) of 1.1 mm (10) or
a urinary albumin level of 30 mg/g cre-
atinine (11) or at least two of the follow-
ing, abdominal obesity (BMI 25 kg/m
2
and abdominal circumference 85 cm
for men and 90 cm for women), hypo–
HDL cholesterolemia (HDL cholesterol
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(triglyceride level 150 mg/dl), and hy-
pertension (blood pressure 130/85
mmHg). The abdominal circumference
criteriaconformedtoJapaneseguidelines.
Exclusion criteria comprised MI, effort
angina, and unstable angina. Patients
with A1C 10% within 1 month before
enrollment or evidence of nephropathy
(serum creatinine measurement 1.5
mg/dl within 1 month before enrollment)
were excluded. Also excluded were those
with valvular disease, idiopathic cardio-
myopathy, evidence of abnormalities on
rest electrocardiography (ECG) such as
atrial ﬁbrillation, NYHA (New York Heart
Association) class III or IV heart failure at
the time of myocardial perfusion SPECT,
and peripheral arterial disease (Fig. 1).
Estimated glomerular ﬁltration rates
(eGFRs) were calculated according to the
equation proposed by Cockcroft and
Gault (12). On the basis of these criteria,
we selected patients who were asymp-
tomatic in terms of ischemic heart disease
but who had potential event risks from
diabetes complications.
Theinstitutionalreviewboardofeach
hospital approved the study, which com-
plied with the Ethical Guidelines for Epi-
demiological Research in Japan. Written
informed consent was obtained from all
participants before starting the study.
Myocardial perfusion imaging
Stress-rest myocardial perfusion SPECT
images were obtained using the 1-day
technetium-99m–tetrofosmin protocol at
94%oftheinstitutionsandthe2-daypro-
tocol at the remainder. Exercise, dipyrid-
amole, adenosine, and adenosine-
triphosphate stress tests were performed
in 71 15, 7, and 6% of the patients, re-
spectively.Theadministereddoseoftech-
netium-99m–tetrofosmin was 200–400
MBq(average331MBq)fortheﬁrststudy
and 700–800 MBq (748 MBq) for the
second. The gated study proceeded on
patients at rest. Standard SPECT image
acquisition protocols used 64  64 ma-
trices over 360° or 180° rotations.
Quantitative gated SPECT
Myocardial perfusion images of short-
axis, vertical long-axis, and horizontal
long-axis images were generated using
preﬁltering (mainly Butterworth) and
rampﬁlters.AllSPECTimageswereinter-
preted by experienced physicians using a
20-segment model, as in the J-ACCESS
study (3). The results of the segmentation
were comparable with estimations based
on the 17-segment model (13). Each of
the myocardial segments was visually
scored using a 5-point system: 0, normal;
1, mildly reduced; 2, moderately re-
duced;3,severelyreduced;and4,absent.
Totals were calculated as summed stress,
rest, and difference scores (SSS, SRS, and
SDS)asvalidatedbyprecedentprognostic
studies (7). The maximum score was 80
points(20segments4points/segment).
Risk-based grouping was based on two
SSS severity categories: 9 (normal or
mildly abnormal) and 9 (moderately or
severely abnormal) as categorized in the
J-ACCESS study (3).
Quantitative gated SPECT proceeded
asdescribed(3,14).SPECTsliceswerere-
constructed using the standard software
provided by the manufacturer. Gated
SPECT images were analyzed at each in-
stitution using QGS software (Cedars-
Sinai Medical Center, Los Angeles, CA)
with automated processing. Inappropri-
ate edge tracing was manually adjusted.
Valuesforleftventricularejectionfraction
(LVEF, %), end-diastolic volume (EDV,
ml), and end-systolic volume (ESV, ml)
were obtained.
Follow-up survey
Cardiovascular events were investigated
at 1, 2, and 3 years after registration, and
the present ﬁnal prognostic analysis was
based on 3-year follow-up data from 485
of the 513 patients because 7 who under-
went revascularization within 30 days of
registration, 7 who died because of non-
cardiaccauses,and14whodidnotattend
thehospitalwereexcluded.Theendpoint
of the follow-up was hard events deﬁned
as sudden or cardiac death and acute
coronary syndrome. Total events addi-
tionally included severe heart failure re-
quiring hospitalization, percutaneous
coronary intervention, coronary artery
bypass grafting, de novo stable angina,
unstable angina, nonsevere heart fail-
ure, transient ischemic attack of the
brain, as well as stroke, and peripheral
artery disease.
Statistics
Continuous variables are expressed as
means  SD. We applied the Wilcoxon
ranksumtesttocompareresultsfrompa-
tients with and without cardiovascular
events and applied the 
2 test to categor-
ical data. The independent variables in
the univariate Cox proportional hazard
model included age, sex, cardiac risk fac-
tors (chest pain, BMI, hypertension, dys-
lipidemia, diabetes, history of smoking,
family history of coronary artery disease,
and ECG abnormalities), summed perfu-
sion defect scores, quantitative gated
SPECT parameters of ejection fraction
(EF), and volumes. Medications before
thefollow-upwerealsoincluded.Thede-
pendent variable was the occurrence of
total events. The threshold value for
events was an EF of 45% and male and
female subject ESV values of 60 and 40
ml, respectively (13). The relative haz-
ard ratios (HRs) and 95% CIs were
calculated. The multivariate Cox pro-
Figure 1—Study design of J-ACCESS 2 and patient registry.
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forward stepwise method based on sta-
tistically signiﬁcant independent vari-
ables excluding medication in the
univariate Cox proportional hazards
model. Two prognostic severity catego-
ries based on SSS values of 9o r9
were included in the multivariate anal-
ysis. Statistical signiﬁcance was deﬁned
as P  0.05.
RESULTS
Clinical background
Among the criteria for patient registry,
IMT 1.1 mm and urinary albumin 30
Table 1—Comparison of parameters between patients with and without events and low (<9) and high (>9) SSS
Total SSS  9 SSS  9 P Total events No events P
Age (years) 66.8  7.7 66.9  7.7 66.1  7.8 0.428 68.8  7.7 66.5  7.7 0.050
Male sex 280/485 (57.7) 246/438 (56.2) 34/47 (72.3) 0.048 36/62 (59.4) 244/423 (57.7) 0.999
BMI (kg/m
2) 24.8  3.6 24.8  3.6 24.7  3.6 0.845 24.3  3.1 24.8  3.7 0.465
Max IMT (mm) 1.6  0.8 1.7  0.8 1.5  0.7 0.145 1.7  0.6 1.6  0.8 0.604
Complications
Retinopathy 122/485 (25.2) 113/438 (25.8) 9/47 (19.1) 0.411 17/62 (27.5) 105/423 (24.8) 0.777
Neuropathy 95/485 (19.6) 82/438 (18.7) 13/47 (27.7) 0.203 11/62 (17.7) 84/423 (19.9) 0.825
Cerebrovascular accident 49/459 (10.7) 43/414 (10.4) 6/45 (13.3) 0.724 9/58 (15.5) 40/401 (9.9) 0.293
Family history of CAD 27/397 (6.8) 24/358 (6.7) 3/39 (7.7) 0.999 3/48 (6.3) 24/349 (6.9) 1.000
Current smoking 85/458 (18.6) 77/415 (18.6) 8/43 (18.6) 1.000 16/55 (29.1) 69/403 (17.1) 0.050
Medication
Sulfonylurea 218/485 (44.9) 199/438 (45.4) 19/47 (40.4) 0.616 26/62 (41.9) 192/423 (45.4) 0.708
-glucosidase inhibitor 131/485 (27.0) 115/438(26.3) 16/47 (34.0) 0.332 14/62 (22.6) 117/423 (27.7) 0.491
Biguanide 89/485 (18.4) 76/438 (17.4) 13/47 (27.7) 0.124 9/62 (14.5) 80/423 (18.9) 0.510
Pioglitazone 41/485 (8.5) 38/438 (8.7) 3/47 (6.4) 0.794 2/62 (3.2) 39/423 (9.2) 0.180
Glinide 13/485 (2.7) 11/438 (2.5) 2/47 (4.3) 0.819 3/62 (4.8) 10/423 (2.4) 0.480
Insulin 145/485 (29.9) 127/438 (29.0) 18/47 (38.3) 0.248 29/69 (41.9) 119/423 (28.1) 0.039
ACE inhibitor 73/485 (15.1) 71/438 (16.2) 2/47 (4.3) 0.050 8/62 (12.9) 65/423 (15.4) 0.752
Angiotensin II receptor blocker 180/485 (37.1) 157/438 (35.8) 23/47 (48.9) 0.108 23/62 (37.1) 157/423 (37.1) 1.000
Calcium antagonist 207/485 (42.7) 189/438 (43.2) 18/47 (38.3) 0.628 31/62 (50.0) 176/423 (41.6) 0.267
Diuretic 42/485 (8.7) 35/438 (8.0) 7/47 (14.9) 0.185 6/62 (9.7) 36/423 (8.5) 0.950
-blocker 25/485 (5.2) 24/438 (5.5) 1/47 (2.1) 0.521 4/62 (6.5) 21/423 (5.0) 0.852
-blocker 36/485 (7.4) 33/438 (7.5) 3/47 (6.4) 0.999 3/62 (4.8) 33/423 (7.8) 0.568
Statin 169/485 (34.8) 157/438 (35.8) 12/47 (25.5) 0.212 15/62 (24.2) 154/423 (36.4) 0.080
Aspirin 102/485 (21.0) 86/438 (19.6) 16/47 (34.0) 0.034 18/62 (29.0) 84/423 (19.9) 0.137
Ticlopidine 21/485 (4.3) 18/438 (4.1) 3/47 (6.4) 0.726 7/62 (11.3) 14/423 (3.3) 0.011
Biochemical data
Total cholesterol (mg/dl) 200.1  34.7 199.6  34.8 204.4  33.4 0.324 208.9  28.8 198.8  35.3 0.020
LDL cholesterol (mg/dl) 117.5  31.2 116.7  31.1 126.5  30.6 0.133 125.1  26.6 116.6  31.6 0.083
HDL cholesterol (mg/dl) 51.1  14.7 51.2  14.8 50.0  13.4 0.643 51.6  14.3 51.0  14.7 0.672
Triglycerides (mg/dl) 168.6  114.8 169.3  117.9 162.5  82.3 0.988 176.1  117.2 167.6  114.6 0.974
Fasting blood glucose (mg/dl) 157.9  54.7 157.3  54.6 164.1  56.7 0.218 171.4  65.4 155.9  52.8 0.065
A1C (%) 7.5  1.2 7.5  1.2 7.5  1.3 0.873 7.3  1.0 7.5  1.2 0.363
Blood urea nitrogen (mg/dl) 16.8  5.1 16.7  5.0 18.2  5.2 0.032 18.7  6.7 16.5  4.7 0.065
Creatinine (mg/dl) 0.8  0.2 0.8  0.2 0.8  0.3 0.173 0.8  0.3 0.8  0.2 0.356
Urinary albumin (mg/g Cre) 159.1  408.0 154.7  415.1 200.6  337.5 0.017 201.7  323.5 154.3  416.8 0.140
Log	urinary albumin (mg/g Cre)
 3.9  1.4 3.9  1.4 4.5  1.2 0.018 4.3  1.5 3.9  1.4 0.148
eGFR (ml/min) 82.3  27.7 82.1  27.6 84.5  29.3 0.633 73.5  22.8 83.6  28.2 0.014
ECG
ECG abnormality at rest 89/426 (20.9) 79/381 (20.7) 10/45 (22.2) 0.969 16/54 (29.6) 73/372 (19.6) 0.131
Ischemia on stress ECG 50/180 (27.8) 41/156 (26.3) 9/24 (37.5) 0.342 6/24 (25.0) 44/156 (28.2) 0.342
Wall motion abnormality 8/178 (4.5) 4/153 (2.6) 4/25 (16.0) 0.013 3/26 (11.5) 5/152 (3.3) 0.172
Nuclear studies
EDV (ml) 73.6  22.1 71.6  19.9 92.1  31.2 0.001 73.6  23.9 73.6  21.8 0.839
ESV (ml) 25.2  13.1 23.9  11.7 37.7  18.6 0.001 26.9  14.0 24.9  13.0 0.429
LVEF (%) 67.4  9.8 68.1  9.5 60.4  9.1 0.001 64.8  10.8 67.8  9.6 0.090
SSS 2.8  4.6 1.6  2.3 14.1  5.4 0.001 3.6  5.0 2.7  4.5 0.364
SSS 9 47/485 (9.7) — — 11/62 (17.7) 36/423 (8.5) 0.039
SRS 2.1  3.7 1.4  2.3 9.3  6.2 0.001 2.4  3.9 2.1  3.7 0.875
SDS 0.7  2.8 0.3  1.5 4.8  6.5 0.001 1.2  3.5 0.6  2.7 0.202
Data are means  SD or n/total (%). CAD, coronary artery disease.
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36% of the patients, respectively. The fre-
quencyoftheothercriteriawashyperten-
sion (blood pressure 130/85 mmHg or
takinghypotensivedrugs)in81%,hyper-
triglyceridemia (triglyceride level 150
mg/dl, HDL cholesterol level 40 mg/dl,
or taking hypolipidemic drugs) in 80%,
and abdominal obesity in 21%. BMI was
24.83.6kg/m
2,andIMTwas1.60.8
mm. With respect to other risk factors,
19% of patients were current smokers,
and 7% had a family history of coronary
artery disease. Rest ECG ﬁndings were
atypical in 89 (21%) of 426 (88%) of the
patients.ExerciseECGﬁndingssuggested
myocardial ischemia in 50 (28%) of 180
(37% of the total) patients (Table 1).
Death and cardiovascular events
during follow-up
Five patients died during the 3-year fol-
low-up, three due to sudden death and
two to cardiac death. 9 patients were di-
agnosed with nonfatal acute coronary
syndrome, 3 developed heart failure re-
quiring hospitalization, 10 were diag-
nosed with stable angina pectoris, and 3
were diagnosed with nonsevere heart fail-
ure. Cerebrovascular accidents and tran-
sient ischemic attacks occurred in 15 and
2 patients, respectively, and 6 patients
were diagnosed with peripheral artery
disease. Recurrent and initial percutane-
ous coronary intervention proceeded in
one and six patients, respectively. Other
cardiovascular accidents occurred in two
patients.
Figure 2 shows Kaplan-Meier curves
for event-free survival for cardiac events.
At the end of follow-up, the event-free
rates were 0.88 and 0.77 for the groups
with low and high SSS, respectively (P 
0.009). The urinary excretion rate of al-
bumin was higher in the high SSS group
(P  0.017). ECG revealed a higher inci-
dence of segmental wall motion abnor-
malities (P  0.013) and the myocardial
perfusion defect scores of SRS and SDS
werehigher(bothP0.0001)inthehigh
SSS group. Both EDV and ESV were
higher, whereas EF was lower in the high
SSS group (all P  0.0001; Table 1).
The following event summary is
based on sudden or cardiac death and
nonfatal cardiovascular events. Table 1
compares patients with and without
events. Patients with events were older
(P  0.05) and had higher total choles-
terol levels (P  0.020). They also had a
signiﬁcantly lower eGFR (P  0.014) and
were frequently medicated with ticlopi-
dine (P  0.011) or insulin (P  0.039).
The results of nuclear studies did not sig-
niﬁcantly differ.
Univariate analysis showed that the
signiﬁcant variables for total events were
age, current smoking, use of insulin or
ticlopidine, high total cholesterol level,
low eGFR, low LVEF, and SSS 9 (Table
2). Multivariate Cox regression analysis
applied using these signiﬁcant variables
but excluding medication revealed that
SSS 9 (HR 3.385 [95% CI 1.783–
6.426]; P  0.0002), eGFR (0.982
[0.971–0.992];P0.0008),andcurrent
smoking (2.083 [1.194–3.632]; P 
0.0097) were independent predictors of
cardiac events.
CONCLUSIONS — Coronary artery
disease is a leading cause of death among
Western and Japanese patients with dia-
betes. The prevalence of diabetes in the
Japanese population is rapidly increasing
as the lifestyle becomes more Western-
ized. Therefore, the cardiovascular event
rate among asymptomatic diabetic Japa-
nese patients is a matter of considerable
concern.
The rate of cardiac deaths and cardio-
vascular events among patients with type
2 diabetes in the J-ACCESS 2 population
during the 3-year follow-up was 13%.
Scholte et al. (15) found a comparable
rate of cardiovascular events in 6 (5%) of
120 patients during a follow-up period
of 12 months, whereas the Detection
of Ischemia in Asymptomatic Diabetics
(DIAD)-2 study identiﬁed a 0.6% annual
cardiovascular event rate among asymp-
tomatic diabetic patients (16). The offset-
ting factors of healthier patients capable
of exercise testing and more intensive
therapy might have been associated with
the rather low cardiac event rate in the
DIAD-2 study. Asymptomatic patients
were selected in the J-ACCESS 2 investi-
gation from the viewpoint of coronary ar-
tery disease but with potential event risks
included in the selection criteria. In addi-
tion, because the patients were indicated
for myocardial perfusion imaging by a
physician, patients with relatively higher
risk might have been included.
The rate of cardiac deaths and cardio-
vascular events in the J-ACCESS 2 study
was 2.7-fold higher than that of recent
epidemiological surveys conducted by
the Japanese Diabetes Society (17). The
rate of cardiovascular events excluding
noncardiac death and heart failure in the
J-ACCESS 2 study of 56 events over a pe-
riod of 3 years was also 2.3-fold higher
than that (1.7% per annum) of the non-
aspirin group in the more recent Japanese
Primary Prevention of Atherosclerosis
with Aspirin for Diabetes (JPAD) study of
asymptomaticJapanesepatientswithtype
2 diabetes (18). Furthermore, this high
cardiovascular event rate was quite com-
parable with those of groups given inten-
sive and standard treatment (22.1 and
22.4% over a period of 5 years, respec-
tively)intheADVANCEtrialandwiththe
ﬁndings of the ACCORD trial (19,20).
The J-ACCESS study demonstrated re-
markably low cardiovascular risk among
Japanese, even among those with type 2
diabetes (3). Asymptomatic patients with
type 2 diabetes were enrolled for the J-
ACCESS 2 study, and we validated mark-
Figure 2—Event-free survival in low (9) and high (9) SSS groups.
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mm (10), a urinary albumin level of 30
mg/g creatinine (11), and at least two of
the four relevant conditions to ensure the
registration of those with appropriate di-
agnostic yields. Considering the substan-
tial difference in cardiovascular event
rates between Western and Japanese dia-
beticpatients,weconsiderthatthesecon-
ditions for enrolment into J-ACCESS 2
might have speciﬁcally selected diabetic
patients at high risk for cardiovascular
diseases.
The role of SPECT for detecting myo-
cardial ischemia has been validated (5,6),
and general consensus has also been
reached regarding prognostic evaluation.
Because the risk of cardiac death and MI
increases with increasing degrees of scan
abnormalities, the summed score is now
widelyacceptedasdescribedintheguide-
lines of the American Cardiology Society
(7). The rate of sudden or cardiac deaths
and cardiovascular events in the J-
ACCESS2populationwithasymptomatic
type 2 diabetes was 1.9-fold higher
among individuals with high than with
lowSSS.Thecardiaceventrate(including
hospitalization and sudden or cardiac
death) was 1.9-fold higher among dia-
betic patients with than without myocar-
dial ischemia evaluated by myocardial
perfusion scintigraphy in the MERIDIAN
(Multicentre Trial of Early Revascularisa-
tion In Patients with Diabetes Mellitus
Type 2 and Mild Anginal Symptoms) trial
(21).
To apply the multivariate model, the
total numbers of patients and events were
limited from the ﬁnal analysis. We there-
foreusedﬁvevariableswiththesmallestP
values according to the univariate Cox
proportional hazards model. Current
smokingandaloweGFR,aswellasahigh
SSS, were found to be independently as-
sociated with the increased rate of cardio-
vascular events in the present study. A
large-scale community-based population
study revealed an independent, graded
association between a reduced eGFR and
the risk of death and cardiovascular
events (22). Irie et al. (23) also found in a
10-year prospective cohort study that in-
dividuals with a reduced eGFR had a
1.65- or 1.81-fold higher risk of cardio-
vascular diseases . Univariate Cox hazard
analysis revealed a higher incidence of
cardiovascular events among patients
treatedwithinsulinorticlopidineatbase-
line. Further analyses on possible affec-
tion of baseline medication or additional
medication on total events in the J-
ACCESS 2 study might clarify the clinical
meaning of these observations.
Limitations
Each patient was scored at one of the 50
participating institutions because collect-
ing and evaluating all images at a core
center was unfeasible. However, variabil-
ity of SSS and SRS scores among these
institutions was acceptable, and the pre-
Table 2—Univariate Cox regression model for all cardiovascular events
HR (95% CI) P
Age 1.037 (1.003–1.073) 0.031
Male sex 0.984 (0.594–1.629) 0.950
BMI (kg/m
2) 0.960 (0.893–1.031) 0.263
Max IMT (mm) 1.008 (0.633–1.605) 0.973
Complications
Retinopathy 1.061 (0.796–1.413) 0.688
Neuropathy 0.897 (0.467–1.720) 0.743
Cerebrovascular accident 1.612 (0.792–3.281) 0.188
Family history of CAD 0.901 (0.280–2.900) 0.862
Current smoking 1.850 (1.034–3.310) 0.038
Medications
Sulfonylurea 0.880 (0.531–1.458) 0.620
-glucosidase inhibitor 0.783 (0.432–1.421) 0.422
Biguanide 0.725 (0.358–1.469) 0.372
Pioglitazone 0.349 (0.086–1.429) 0.143
Glinide 2.152 (0.675–6.862) 0.195
Insulin 1.781 (1.075–2.949) 0.025
ACE inhibitor 0.819 (0.390–1.720) 0.598
Angiotensin II receptor blocker 1.012 (0.605–1.695) 0.963
Calcium antagonist 1.356 (0.824–2.231) 0.230
Diuretic 1.155 (0.497–2.679) 0.738
-blocker 1.314 (0.477–3.617) 0.598
-blocker 0.611 (0.192–1.949) 0.405
Statin 0.572 (0.320–1.023) 0.060
Aspirin 1.608 (0.929–2.782) 0.090
Ticlopidine 3.237 (1.474–7.108) 0.003
Biochemical data
Total cholesterol (mg/dl) 1.007 (1.000–1.014) 0.041
LDL cholesterol (mg/dl) 1.008 (0.997–1.019) 0.152
HDL cholesterol (mg/dl) 1.002 (0.985–1.020) 0.794
Triglycerides (mg/dl) 1.000 (0.999–1.002) 0.634
Fasting blood glucose (mg/dl) 1.004 (1.000–1.008) 0.059
A1C (%) 0.877 (0.707–1.089) 0.234
Blood urea nitrogen (mg/dl) 1.064 (1.022–1.107) 0.002
Creatinine (mg/dl) 2.114 (0.773–5.784) 0.145
Urinary albumin (mg/g Cre) 1.000 (1.000–1.001) 0.534
Log	urinary albumin (mg/g Cre)
 1.223 (0.950–1.575) 0.119
eGFR (ml/min) 0.986 (0.975–0.996) 0.009
ECG
ECG abnormality at rest 1.680 (0.937–3.014) 0.082
Ischemia on stress ECG 1.093 (0.729–1.638) 0.667
Wall motion abnormality 2.847 (0.855–9.487) 0.088
Nuclear studies
SSS 1.036 (0.992–1.083) 0.114
SSS  9 2.322 (1.210–4.455) 0.011
SRS 1.020 (0.959–1.085) 0.530
SDS 1.060 (0.995–1.129) 0.073
LVEF at rest 0.971 (0.946–0.996) 0.023
EDV at rest 1.000 (0.989–1.012) 0.970
ESV at rest 1.010 (0.993–1.027) 0.263
CAD, coronary artery disease.
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rameters regarding EF and volumes was
excellent (14).
The frequency of a high SSS was
lower in the J-ACCESS 2 (10%) than in
the J-ACCESS study (34%). The inci-
dence of major cardiac events including
sudden or cardiac death, acute coronary
syndrome,andsevereheartfailurerequir-
ing hospitalization during a 3-year fol-
low-up in J-ACCESS 2 was 3.5% (17 of
485), which is a little lower than that of
diabetic patients without prior MI in the
J-ACCESS study (5.7%). Ongoing analy-
sis of the treatment modality might sup-
port the decreased rate of major cardiac
events in J-ACCESS 2.
In conclusion, the cardiovascular
event rate was high and comparable
amongasymptomaticJapaneseandWest-
ern diabetic patients. Abnormal myocar-
dialperfusionimagesmightbeprognostic
forafurthertwofoldhigherriskofcardio-
vascular disease among asymptomatic di-
abetic patients with conventional
cardiovascularriskssuchasdyslipidemia,
hypertension, and abdominal obesity, as
well as high carotid atherosclerosis or
microalbuminuria.AreducedeGFRand
current smoking were other indepen-
dent predictors for identifying high-
risk groups among asymptomatic dia-
betic patients. The present data indicate
that myocardial ischemia would be use-
ful for risk stratiﬁcation of cardiovascu-
lar events in asymptomatic diabetic
patients.
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